Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Under the Medicaid system, individual states are allowed to decide whether to cover GLP-1 drugs, which include Wegovy (semaglutide),… read on > read on >



















